Autolus Therapeutics (AUTL) Cash & Equivalents (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Cash & Equivalents for 9 consecutive years, with $104.1 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents fell 54.2% year-over-year to $104.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $104.1 million (down 54.2% YoY) and the FY2025 annual result came in at $104.1 million, down 54.2% from the prior year.
• Cash & Equivalents improved to $104.1 million in Q4 2025 per AUTL's latest filing, from $86.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for AUTL reached as high as $758.5 million in Q1 2024 and fell as low as $86.1 million in Q3 2025.
• A 5-year average of $293.7 million and a median of $239.3 million in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 156.25% — and 2025, when it tumbled 87.37%.
• Year by year, Cash & Equivalents stood at $310.3 million in 2021, then gained by 23.23% to $382.4 million in 2022, then tumbled by 37.36% to $239.6 million in 2023, then fell by 5.09% to $227.4 million in 2024, then plunged by 54.2% to $104.1 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $104.1 million, $86.1 million, and $123.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.